Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming
The worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%. Patients with NASH, especially those with fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality. Although...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Diabetes Association
2020-10-01
|
| Series: | Diabetes & Metabolism Journal |
| Subjects: | |
| Online Access: | http://www.e-dmj.org/upload/pdf/dmj-2020-0115.pdf |
| _version_ | 1818113608598421504 |
|---|---|
| author | Soung Won Jeong |
| author_facet | Soung Won Jeong |
| author_sort | Soung Won Jeong |
| collection | DOAJ |
| description | The worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%. Patients with NASH, especially those with fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality. Although vitamin E, pioglitazone, and liraglutide improved liver histology in randomized trials, there are currently no Food and Drug Administration-approved drugs for NASH. Five pharmacologic agents—obeticholic acid, elafibranor, cenicriviroc, resmetirom, and aramchol—are being evaluated in large, histology-based phase 3 trials. Within 2 to 4 years, new and effective drugs for the treatment of NASH are expected. Additionally, many phase 2 trials are ongoing for various agents. Based on the results of phase 2 and 3 trials, combination treatments are also being investigated. Future treatment strategies will comprise drug combinations and precision medicine based on the different phenotypes of NASH and treatment response of the individual patient. |
| first_indexed | 2024-12-11T03:37:32Z |
| format | Article |
| id | doaj.art-28208cc896174ed990314341e970bcc9 |
| institution | Directory Open Access Journal |
| issn | 2233-6079 2233-6087 |
| language | English |
| last_indexed | 2024-12-11T03:37:32Z |
| publishDate | 2020-10-01 |
| publisher | Korean Diabetes Association |
| record_format | Article |
| series | Diabetes & Metabolism Journal |
| spelling | doaj.art-28208cc896174ed990314341e970bcc92022-12-22T01:22:12ZengKorean Diabetes AssociationDiabetes & Metabolism Journal2233-60792233-60872020-10-0144564065710.4093/dmj.2020.01151799Nonalcoholic Fatty Liver Disease: A Drug Revolution Is ComingSoung Won Jeong0 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, KoreaThe worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%. Patients with NASH, especially those with fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality. Although vitamin E, pioglitazone, and liraglutide improved liver histology in randomized trials, there are currently no Food and Drug Administration-approved drugs for NASH. Five pharmacologic agents—obeticholic acid, elafibranor, cenicriviroc, resmetirom, and aramchol—are being evaluated in large, histology-based phase 3 trials. Within 2 to 4 years, new and effective drugs for the treatment of NASH are expected. Additionally, many phase 2 trials are ongoing for various agents. Based on the results of phase 2 and 3 trials, combination treatments are also being investigated. Future treatment strategies will comprise drug combinations and precision medicine based on the different phenotypes of NASH and treatment response of the individual patient.http://www.e-dmj.org/upload/pdf/dmj-2020-0115.pdfdrug therapy, combinationfibrosisnon-alcoholic fatty liver diseaseprecision medicinetherapeutics |
| spellingShingle | Soung Won Jeong Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming Diabetes & Metabolism Journal drug therapy, combination fibrosis non-alcoholic fatty liver disease precision medicine therapeutics |
| title | Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming |
| title_full | Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming |
| title_fullStr | Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming |
| title_full_unstemmed | Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming |
| title_short | Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming |
| title_sort | nonalcoholic fatty liver disease a drug revolution is coming |
| topic | drug therapy, combination fibrosis non-alcoholic fatty liver disease precision medicine therapeutics |
| url | http://www.e-dmj.org/upload/pdf/dmj-2020-0115.pdf |
| work_keys_str_mv | AT soungwonjeong nonalcoholicfattyliverdiseaseadrugrevolutioniscoming |